Neurocrine Biosciences company profile
Company profile
Neurocrine Biosciences has 2,500 employees and is headquartered in San Diego, United States.
Neurocrine Biosciences sells its medicines mainly to patients with neurological and psychiatric disorders, and to patients with endocrine and immunological conditions, in the United States and in other markets outside the country. Its marketed products include INGREZZA, for tardive dyskinesia and chorea linked to Huntington's disease, Orilissa and Oriahnn for gynecological conditions, and CRENESSITY for congenital adrenal hyperplasia, alongside ALKINDI and Efmody. Its pipeline in clinical development targets movement disorders, major depressive disorder, schizophrenia, Alzheimer's disease, epilepsy and obesity. The company also works under license and collaboration agreements with partners including Takeda, Sanofi, AbbVie and Xenon Pharmaceuticals.
In the fiscal year ended December 2025, Neurocrine Biosciences reported revenue of 2.9 billion US dollars, up 21.4% from the previous year, and net income of 478.6 million US dollars. The company was founded in 1992 and is headquartered in San Diego, California, with 2,500 employees.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Headquarters
- 6027 Edgewood Bend Court, 92130, San Diego
- Employees
- 2,500
- Chief executive
- Kyle Gano
- Founded
- 1992
- Fiscal year
- January - December
- Listing
- NBIX · NASDAQ
- Currency
- USD
- ISIN
- US64125C1099
- Website
- neurocrine.com
Neurocrine Biosciences and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Neurocrine BiosciencesNBIX | United States | $16.73B | 2,500 | 26.6% | 24.5 |
| ViatrisVTRS | United States | $23.58B | 30,000 | — | — |
| United TherapeuticsUTHR | United States | $25.04B | 1,400 | 39.4% | 22.2 |
| ZoetisZTS | United States | $33.92B | 14,500 | 37.9% | 14.1 |
| Teva Pharmaceutical IndustriesTEVA | United States | $49.67B | 31,173 | 19.8% | 99.0 |
| Hims & Hers HealthHIMS | United States | $4.13B | 2,442 | -6.4% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
